Embryonal rhabdomyosarcoma

Embryonal rhabdomyosarcoma (ERMS) is the most common subtype of rhabdomyosarcoma, a malignant soft tissue tumor that arises from primitive mesenchymal cells committed to skeletal muscle differentiation. It predominantly affects children, with the majority of cases diagnosed before the age of 10 years. ERMS most commonly occurs in the head and neck region (including the orbit, nasopharynx, and parameningeal sites), the genitourinary tract (bladder, prostate, vagina, paratesticular region), and less frequently in the extremities, retroperitoneum, and biliary tract. The tumor presents as a rapidly growing mass, and symptoms depend on the site of origin — for example, proptosis or nasal obstruction for head and neck tumors, urinary retention or hematuria for genitourinary tumors, or a painless swelling in the paratesticular region. Histologically, embryonal rhabdomyosarcoma is characterized by small round to spindle-shaped cells with variable degrees of skeletal muscle differentiation. Specific histologic variants include the botryoid subtype, which forms grape-like polypoid masses in hollow organs such as the vagina or bladder, and the spindle cell variant. Immunohistochemistry typically shows positivity for desmin, myogenin, and MyoD1. The tumor frequently demonstrates loss of heterozygosity at chromosome 11p15.5, and unlike the alveolar subtype, ERMS generally lacks the characteristic PAX3-FOXO1 or PAX7-FOXO1 fusion genes. Treatment of embryonal rhabdomyosarcoma involves a multimodal approach including surgical resection when feasible, multi-agent chemotherapy (typically vincristine, actinomycin D, and cyclophosphamide — the VAC regimen), and radiation therapy for patients with residual or unresectable disease. ERMS generally carries a more favorable prognosis compared to alveolar rhabdomyosarcoma, particularly when diagnosed at an early stage and in favorable anatomic sites. Five-year survival rates for localized disease can exceed 70-80% with current treatment protocols. Risk stratification based on stage, group (extent of surgical resection), age, and tumor site guides treatment intensity. Some patients may be eligible for clinical trials investigating targeted therapies or novel chemotherapy combinations.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Embryonal rhabdomyosarcoma